NCT06470178尚未招募不适用
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Colorectal Cancer With Chemotherapy Combined With Anti-Angiogenic Targeted Agents
Wuhan University1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2025年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Corhot2: R0 surgical conversion rate
研究概览
简要总结
Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer, but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advanced/advanced colorectal cancer has not yet been reported. This study aims to observe the efficacy and safety of fruquintinib combined with chemotherapy in neoadjuvant or conversion therapy for colorectal cancer patients in the real world.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following criteria to be enrolled in this study:
- •Age ≥18 years and ≤75 years;
- •Either gender;
- •Patients with histologically confirmed colorectal cancer. For the neoadjuvant treatment cohort: Rectal cancer is limited to high rectal cancer, but patients with mid to low rectal cancer who are unwilling or unsuitable for neoadjuvant chemoradiotherapy can also be included.
- •Neoadjuvant treatment cohort: Clinically staged as stage II (T3-4N0M0) or stage III (T1-4N1-2M0) and initially resectable; patients with clinical stage M1 but initially resectable can also be included in the neoadjuvant treatment cohort, such as patients with stage IV liver oligometastasis. Conversion treatment cohort: Patients with initially unresectable but potentially resectable locally advanced or advanced distant metastatic colorectal cancer (according to AJCC 8th), and patients with locally advanced low rectal cancer who are unsuitable or unwilling to undergo chemoradiotherapy can also be included.
- •Have received chemotherapy and fruquintinib for at least 2 cycles. For the neoadjuvant therapy cohort, patients who have not previously received anticancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy, etc.). The patients are eligible for inclusion in the analysis set if they have received fruquintinib treatment for at least 2 cycles and have undergone at least one tumor assessment after baseline. All patients included in the efficacy analysis are included in the safety analysis set.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 before treatment.
- •Expected survival time of >6 months before neoadjuvant therapy and >3 months before conversion therapy.
- •No significant organ dysfunction or drug contraindications before receiving neoadjuvant or conversion therapy.
- •There is no mandatory requirement for target lesions. Objective response rate (ORR) assessment is based on all evaluable patients, regardless of the presence of target lesions. For patients without target lesions, those assessed as non PR/non PD will be analyzed as stable disease (SD).
排除标准
- •Patients meeting any of the following criteria are not eligible to enter the study:
- •History of other primary malignant tumors, except: (1) complete remission of malignant tumors at least 2 years before enrollment and no need for other treatment during the study period; (2) adequately treated non-melanoma skin cancer or malignant melanoma without evidence of disease recurrence; (3) adequately treated in situ carcinoma.
- •dMMR/MSI-H.
- •Female patients who are pregnant or lactating.
- •Known allergy (Grade 3 or higher allergic reaction) or contraindication to anti-angiogenic drugs or chemotherapy drug components.
- •Use of non-study drug treatments during the study period that may interfere with the analysis.
- •Patients who did not undergo any tumor efficacy assessment after receiving neoadjuvant or conversion therapy.
- •Less than 2 cycles of fruquintinib neoadjuvant or conversion therapy.
- •Patients with insufficient follow-up information as judged by the investigator (such as not returning to the hospital for treatment or efficacy assessment after initial treatment).
结局指标
主要结局
Corhot2: R0 surgical conversion rate
时间窗: Time from the first treatment up to 24 weeks
R0 surgical conversion rate：The proportion of subjects who achieve complete R0 resection of both the primary gastric lesion and any metastases among all subjects receiving the conversion therapy regimen.
Corhot1: Pathological Complete Response Rate (pCR)
时间窗: Time from the first treatment up to 12 weeks
Pathological Complete Response Rate (pCR), defined as no residual tumor cells in the surgical specimen of the primary tumor and lymph nodes (ypT0N0); corresponds to TRG grade 0.
次要结局
- Corhot1 and Corhot2: Objective Response Rate (ORR)(corhot1 ：Time from the first treatment up to 12 weeks. Corhot2：Time from the first treatment up to 2 years.)
- Corhot1: Event-Free Survival (EFS)(Time from the first treatment up to 2 years)
- Corhot1 and Corhot2: Overall Survival (OS)(Time from the first treatment up to 2 years.)
- Corhot1: R0 resection rate(Time from the first treatment up to 12 weeks)
- Corhot1and Corhot2: Adverse events(through study completion, an average of 1 year)
- Corhot1: 1-year Event-Free Survival (EFS) rate(Time from the first treatment up to 12 months.)
- Corhot1 and Corhot2: 1-year Overall Survival (OS) rate(Time from the first treatment up to 12 months.)
- Corhot1 and Corhot2: Disease Control Rate (DCR)(corhot1 ：Time from the first treatment up to 12 weeks. Corhot2：Time from the first treatment up to 2 years.)
- Corhot2: Curative Surgery Conversion Rate(Time from the first treatment up to 24 weeks)
- Corhot2: Progression-Free Survival (PFS)(Time from the first treatment up to 2 years.)
研究者
Bin Xiong, MD
Chief Physician
Wuhan University
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal CancerMetastatic Colorectal CancerRefractory Colorectal CarcinomaColorectal CancerNCT06221423Fudan University20
招募中
不适用
Fruquintinib in the Cross-line Treatment of Refractory mCRCFruquintinibMetastatic Colorectal CancerNCT06099314Wuhan Union Hospital, China36
进行中（未招募）
2 期
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC PatientsMetastatic Colorectal CancerNCT06403709Cancer Institute and Hospital, Chinese Academy of Medical Sciences35
已完成
2 期
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal CancerRectal CancerNCT02217020Sun Yat-sen University100
已完成
不适用
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world StudyRefractory Colorectal CancerMetastatic Colorectal CancerColorectal CancerNCT06202417Fudan University520